Syantra Partners with Mays Cancer Center to Advance Breast Cancer Detection via Clinical Studies

Collaboration to Revolutionize Breast Cancer Detection

Syantra, Inc., a groundbreaking biotechnology firm specializing in cancer detection solutions, recently announced a strategic collaboration with the Mays Cancer Center at the University of Texas Health Science Center in San Antonio. This partnership is backed by new funding attained from Alberta Innovates, aimed at bolstering clinical studies of Syantra's Onco-ID™ Breast blood test, specifically tailored for women at heightened risk of breast cancer.

The funding originates from the Accelerating Innovations into CarE (AICE) Market Access program by Alberta Innovates. This grant comes in addition to previous financial support from the United States Department of Defense, further exemplifying the urgency and importance of Syantra's research initiatives.

The CEO of Syantra, Rob Lozuk, expressed gratitude for the recognition accompanying the AICE award, noting the significance it holds for continuing their innovative work. He stated, "This transformative grant allows us to harness our scientific capabilities to enhance early detection of cancer, which is critical for patient outcomes."

This funding is intended to enhance critical documentation processes necessary for FDA filing, aiding Syantra's entry into the U.S. market. The forthcoming studies will primarily focus on women with dense breast tissue—those considered at higher risk—and will also involve pilot data collection on the Onco-ID™ test’s efficacy in real-world settings.

Dr. Jessica Treviño Jones, who leads this joint effort, is a highly regarded associate professor and breast medical oncologist at the Mays Cancer Center. She also heads the Cancer Risk Reduction and Education Clinic within the institution. Her collaboration aims not just to conduct studies, but also to foster a deeper understanding of breast cancer screening and early detection methodologies.

Dr. Kristina Rinker, Syantra’s co-founder and project lead, highlighted the project's ambition, stating, "We plan to enlist 500 new participants for our clinical validation study within these two years, supporting recruitment on a global level. The data we gather here will be pivotal in determining the commercial application of our Onco-ID test."

As Syantra prepares for these vital endeavors, Lozuk remarked on the momentum the company is gaining, particularly with backing from AICE, the Department of Defense, and the strategic guidance offered by their newly formed Scientific Advisory Board. He confidently declared, "2025 is poised to be a landmark year for Syantra and its commitment to advancing cancer detection technology."

Looking Ahead

Founded in Calgary, Syantra Inc. is dedicated to pioneering technologies that promise to change the landscape of cancer detection and management. The collaboration with Mays Cancer Center marks an important step in validating the effectiveness of the Onco-ID™ platform, leveraging patients' immune responses to identify early-stage cancer.

As they progress towards market readiness, Syantra continues to prioritize innovation and patient safety, ensuring that their groundbreaking methods deliver on the promise of early breast cancer detection—an outcome that can save lives and transform future treatment protocols.

For more information on Syantra and its innovative projects, visit Syantra's website or reach out via email at info@syantra.com.